home / stock / gild / gild articles

GILD Articles, Gilead Sciences Inc. - From 04/19/24

Stock Information
Company Name: Gilead Sciences Inc.
Stock Symbol: GILD
Market: NASDAQ
Website: gilead.com
Menu
GILD GILD Quote GILD Short GILD News GILD Articles GILD Message Board
Get GILD Alerts

News, Short Squeeze, Breakout and More Instantly...
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies | Benzinga

Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings??...
If You Invested $100 In This Stock 20 Years Ago, You Would Have $900 Today | Benzinga

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 3.77% on an annualized basis producing an average annual return...

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter | Benzinga

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...

Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst | Benzinga

Bank of America Securities downgrades European drugmaker Galapagos NV (NASDAQ:GLPG) to underperform, citing few catalysts in the near term. Gal...
Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session - Here's Why | Benzinga

Xilio Therapeutics Inc (NASDAQ:XLO) shares are surging as the company announced an exclusive license agreement with Gilead Sciences Inc&n...

Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production | Benzinga

Gilead Sciences Inc’s (NASDAQ:GILD) executive revealed the company’s plans to increase its production of cell therapy cancer treat...

If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,100 Today | Benzinga

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 4.71% on an annualized basis producing an average annual return...
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley | Benzinga

Morgan Stanley initiates Arcellx Inc (NASDAQ:ACLX), noting a differentiated CAR-T platform for blood cancer backed by an established...

Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead's and Merck's Combo Therapy | Benzinga

Gilead Sciences Inc (NASDAQ:GILD) and Merck & Co Inc (NYSE:MRK) released results from the Phase 2 clinical study evaluating the ...

Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers | Benzinga

Biogen Inc (NASDAQ:BIIB) released interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study. The Ph...
Previous 10 Next 10